Home Biosimilar Antibodies Immunology & Inflammation Interleukins Siltuximab (anti-IL-6)
For research use only. Not for use in humans.

Siltuximab (anti-IL-6)

Synonyms: IL-6， BSF-2

Siltuximab (anti-IL-6) (CNTO 328) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6).

Siltuximab (anti-IL-6)

Click to purchase the isotype control of Siltuximab (anti-IL-6)

2 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A203002 Purity: 99.93% Protein concentration: 5.6mg/ml Endotoxin Level: ＜1EU/mg
99.93

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Siltuximab (anti-IL-6) (CNTO 328) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6).
References

Product Details

CAS No. 541502-14-1
Molecular Weight 145 kDa
Isotype Human IgG1, κ
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07709000 NOT_YET_RECRUITING Drug: Acetaminophen (or similar antipyretic)|Drug: Diphenhyd Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Hematologic Malignancies Merck Sharp & Dohme LLC 2026-09-11 PHASE2
NCT07570173 RECRUITING Drug: Acetaminophen|Drug: Diphenhydramine|Drug: Dexamethason B-cell Acute Lymphoblastic Leukemia Merck Sharp & Dohme LLC 2026-05-18 PHASE2; PHASE3
NCT05305066 RECRUITING Drug: TNFi|Drug: Anti-IL6|Drug: JAKi Rheumatoid Arthritis Marie Hudson, MD 2023-02-01
NCT06447376 RECRUITING Drug: Siltuximab|Drug: Epcoritamab|Drug: Gemcitabine and oxa Non-Hodgkin Lymphoma; Cytokine Release Syndrome Taylor Brooks 2025-01-14 PHASE1
NCT06990711 RECRUITING Drug: Siltuximab|Drug: Placebo Antibody Mediated Rejection of Lung Transplant Washington University School of Medicine 2025-11-06 PHASE1
NCT05684692 RECRUITING Drug: Siltuximab|Drug: Erenumab-Aooe|Drug: Siltuximab Matchi Schwannomatosis; Schwannomas; Pain, Chronic Massachusetts General Hospital 2023-08-31 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.